ポリアミンテストーエンザイムによる尿路性器癌患者における尿中ポリアミンについて

Abstract

ポリアミンテスト-エンザイムのキットを用いて, 泌尿器科領域の悪性腫瘍患者74例(腎細胞癌12例, 腎盂尿管腫瘍13例, 膀胱腫瘍24例および前立腺癌25例), 前立腺肥大症患者7例, 泌尿器科的良性疾患患者20例および健常人20例の尿中ポリアミンを測定した.1)尿路性器癌におけるいずれの疾患群も健常人に比し有意の上昇を認めたが, 前立腺肥大症も同様に有意の上昇を認めた.2)健常人20例の平均+3SD (=50 μmoles/g.Cr.)を尿中ポリアミンの上限値とすると, 前立腺肥大症および泌尿器科的良性疾患において100 μmoles/g.Cr.以下の軽度高値の症例がかなり認められた.3) 100 μmoles/g.Cr.に上限値を設置した結果, 腎細胞癌の陽性率は33%(low stage 17%), 腎盂尿管腫瘍23%(low stage 14%), 膀胱腫瘍13%(low stage 0%)および前立腺癌4%(low stage 0%)であり, 特にlow stageの症例において陽性率が低かった

Using a polyamine-test enzyme kit, the urine polyamine concentration was determined in 74 patients with malignant urological disease (12 with renal cell cancer, 13 with pelvic-ureter cancer, 24 with bladder cancer and 25 with prostate cancer), 7 patients with BPH, 20 patients with benign urological disease and 20 normal subjects. The urine polyamine level was significantly elevated in all the patients with any malignant urological disease compared to normal subjects. It was also significantly high in the patients with BPH. Defining the mean +/- 3SD (= 50 mumole/g Cr.) of 20 normal subjects as an upper limit, slightly higher levels not exceeding 100 mumol/g Cr. were frequently observed in the patients with BPH or with benign urological disease. Setting the upper limit at 100 mumole/g Cr., the positive rate amounted to 33% (low stage 17%) in renal cell cancer, 23% (low stage 14%) in pelvic ureter cancer, 13% (low stage 0%) in bladder cancer and 4% (low stage 0%) in prostate cancer. The positive rate was low especially in low stage cases.